Lei Zhang

zhlei07First product launched 10mo ago

Total monthly visits: 12K; Up23.1%MoMSep 2026Only Glunova Biotech has traffic data
Public revenue: Undisclosed; No public revenue across products
Products: 2; Since Jan 2026
Latest launch: 26d ago; inboxmcpNo traffic data yet

100% full-depth creator dossier open: complete product portfolio, 12-month combined traffic & MRR curves, shipping cadence, and timeline events.

Traffic

Portfolio · Last 12 months

Monthly visits

Products and research metrics
Product	Tagline	Category	Visits · Sep	MoM	Launched	Revenue	Actions
Glunova Biotechglunovabio.comEvidence-based resources for NAD+ Therapy, GLP-1 Medications (Semaglutide, Tirzepatide, Retatrutide), and Cellular Health Optimization	Evidence-based resources for NAD+ Therapy, GLP-1 Medications (Semaglutide, Tirzepatide, Retatrutide), and Cellular Health Optimization	News & Media	12K	Up23.1%	2026-01	Undisclosed
inboxmcpMCPOSSinboxmcp.aiYour email. Your agent. Your priorities.	Your email. Your agent. Your priorities.	Agent Tools & MCP Servers	—	—	2026-10	Undisclosed

Launches, marketing, revenue milestones, and pricing/plan/positioning changes across products

Nov 2 · 12d ago
- Glunova Biotech Added product format: WebFeatures
  —→web
- Glunova Biotech Homepage tagline changed to “Evidence-based resources for NAD+ Therapy, GLP-1 Medications (Semaglutide, Tirzepatide, Retatrutide), and Cellular Health Optimization”Positioning
  What We Do→Evidence-based resources for NAD+ Therapy, GLP-1 Medications (Semaglutide, Tirzepatide, Retatrutide), and Cellular Health Optimization
Oct 20 · 26d ago
- inboxmcp launchedNew product
Jan 17 · 10mo ago
- Glunova Biotech launchedNew product